Nabriva Therapeutics (NASDAQ:NBRV) CEO Ted Schroeder joined Steve Darling from Proactive to discuss the company that is looking to develop innovative anti-infective agents to treat serious infections. Schroeder shares with Proactive more about the company and their products in the pipeline including Xenleta for which the company announced the first patient was enrolled in a Phase 1 clinical trial to assess the safety and pharmacokinetics of oral and intravenous in adult patients with cystic fibrosis. Schroeder also talked about their other products in the pipeline including Sivextro for which they have a distribution partnership with Merch in the United States.
Nabriva Therapeutics enrolls 1st patient in Phase 1 trial of Xenleta for adults with Cystic Fibrosis
